ID
45519
Descrição
Principal Investigator: Eric O. Johnson, PhD, RTI International, Research Triangle Park, North Carolina, USA MeSH: HIV,Viral Load,Substance Abuse, intravenous https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000454 The overarching goal of this project is to identify and characterize genetic determinants of HIV 1 susceptibility and resistance in samples of African American (AA) and European American (EA) injection drug users (IDUs) by conducting (1) a case/control genome-wide association (GWA) study of HIV 1 infection (positive/negative); (2) a case-only GWA study of viral load among HIV+ IDUs. The study uses existing samples and data from Urban Health Study (UHS) (PI: Alex Kral), which was the longest-running study of street-recruited IDUs in North America, from 1986-2005. UHS was a serial, cross-sectional sero-epidemiological study. Data were collected every 6 months in communities with a high prevalence of injection drug use in the San Francisco Bay Area. It used targeted sampling in neighborhoods at easily accessible community field sites, such as churches, single room occupancy hotels, and community centers. Eligibility criteria for initial entry to the study were (1) injection drug use in past 30 days; (2) ability to provide informed consent; and (3) age 18 or older. The UHS cohort includes over 9,000 African American and European American IDUs whose serum samples have been stored and data are available on HIV antibody status, HIV risk behaviors, drug abuse and demographics. The current study includes 984 HIV+ cases and 2,243 HIV- controls. Approximately two HIV- controls per case were frequency matched on: (1) self-reported ancestry; (2) sex; (3) age; (4) year of ascertainment; and (5) HIV risk class. This GWAS (DA026141) was funded by the National Institute on Drug Abuse (NIDA; PI: Eric O. Johnson). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research (CIDR), was provided by NIDA and the NIH contract "High throughput genotyping for studying the genetic contributions to human disease"(HHSN268200782096C).
Link
Palavras-chave
Versões (1)
- 14/12/2022 14/12/2022 - Adrian Schulz
Titular dos direitos
Eric O. Johnson, PhD, RTI International, Research Triangle Park, North Carolina, USA
Transferido a
14 de dezembro de 2022
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
dbGaP phs000454 HIV-1 Host Genetics Among Injection Drug Users
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information
- Subject - Sample Mapping
- The dataset contains data describing participants' case/control status, HIV risk group (Latent Class Analysis, LCA), several LCA indicators (e.g. multiple partners, needle sharing, STD), viral load, and provides basic socio-demographic information. Note that multiple measurements (over time) are reported for some variables.
- Pedigree Information
- Sample Attribute Information
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information
- Subject - Sample Mapping
- The dataset contains data describing participants' case/control status, HIV risk group (Latent Class Analysis, LCA), several LCA indicators (e.g. multiple partners, needle sharing, STD), viral load, and provides basic socio-demographic information. Note that multiple measurements (over time) are reported for some variables.
- Pedigree Information
- Sample Attribute Information
C0680251 (UMLS CUI [1,2])